Study: NCT00908960

Adverse event: Disease progression
Serious: no
Organ System: Investigations
Notes: These subjects had disease progression: 3 Lung cancer on observation; 1 pancreatic cancer on observation; 1 pancreatic cancer on lovenox and another lung cancer on lovenox.
Frequency: 2 affected / 23 at risk

Adverse event: Platelets
Serious: no
Organ System: Blood and lymphatic system disorders
Notes: Subject with lung cancer on lovenox and was found with low platelets. Another subject with colon cancer on observation was also found with low platelets.
Frequency: 1 affected / 23 at risk

Adverse event: Alkaline Phosphotase and aspartate aminotransferase
Serious: no
Organ System: Metabolism and nutrition disorders
Notes: Subject with pancreatic cancer and on lovenox was hospitalized for a decreased urine output, obstructive liver function tests, and ankle edema.
Frequency: 1 affected / 23 at risk

Adverse event: Lymphatics
Serious: no
Organ System: Musculoskeletal and connective tissue disorders
Notes: Subject with lung cancer and on lovenox was hospitalized with increased swelling and discomfort over left side of neck.
Frequency: 1 affected / 23 at risk

Adverse event: pneumonia and anemia
Serious: no
Organ System: Respiratory, thoracic and mediastinal disorders
Notes: subject with pancreatic cancer on lovenox arm was hospitalized for pneumonia and anemia.
Frequency: 1 affected / 23 at risk

Adverse event: Dyspnoea
Serious: no
Organ System: Respiratory, thoracic and mediastinal disorders
Notes: A subject with lung cancer on the observation arm experienced shortness of breath while on trial. Another study subject with pancreatic cancer on the observation arm died following rapidly progressive shortness of breath and hypoxia at nursing home.
Frequency: 1 affected / 11 at risk

Adverse event: Disease progression
Serious: no
Organ System: Investigations
Notes: These subjects had disease progression: 3 Lung cancer on observation; 1 pancreatic cancer on observation; 1 pancreatic cancer on lovenox and another lung cancer on lovenox.
Frequency: 1 affected / 11 at risk

Adverse event: elevated troponin
Serious: no
Organ System: Cardiac disorders
Notes: A pancreatic cancer subject on observation arm with elevated troponin
Frequency: 1 affected / 11 at risk

Adverse event: Dyspnoea
Serious: no
Organ System: Respiratory, thoracic and mediastinal disorders
Notes: A subject with lung cancer on the observation arm experienced shortness of breath while on trial. Another study subject with pancreatic cancer on the observation arm died following rapidly progressive shortness of breath and hypoxia at nursing home.
Frequency: 1 affected / 32 at risk

Adverse event: Disease progression
Serious: no
Organ System: Investigations
Notes: These subjects had disease progression: 3 Lung cancer on observation; 1 pancreatic cancer on observation; 1 pancreatic cancer on lovenox and another lung cancer on lovenox.
Frequency: 3 affected / 32 at risk

Adverse event: Infection
Serious: no
Organ System: Infections and infestations
Notes: A pancreatic cancer subject on observation arm died following a blood infection.
Frequency: 1 affected / 32 at risk

Adverse event: Platelets
Serious: no
Organ System: Blood and lymphatic system disorders
Notes: Subject with lung cancer on lovenox and was found with low platelets. Another subject with colon cancer on observation was also found with low platelets.
Frequency: 1 affected / 32 at risk

Adverse event: GI-Hemorrhage
Serious: no
Organ System: Gastrointestinal disorders
Notes: Study subject with pancreatic cancer on the observation arm died following an gastrointestinal bleed.
Frequency: 1 affected / 32 at risk